EGFR and non-small cell lung carcinoma: Emerging evidence suggests that patients with epidermal growth factor receptor (EGFR) gene mutation–positive NSCLC are particularly prone to BMs, with the frequency of patients with BM ranging from 44% to 63% (Bhatt et al., 2013).